Navigation Links
Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round
Date:2/3/2010

GENEVA, February 3 /PRNewswire/ -- Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).

Jamie Paterson, a British national, can look back at 20 years of experience in the pharmaceutical industry. Prior to joining Viroblock he was Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at Procter & Gamble he held several positions with increasing responsibility including Marketing Manager Italy and Commercial Director Spain. His final position at P&G was European Director of Strategic Planning and New Business Development - Rx & OTC. Jamie holds a PhD in Biochemistry from Imperial College, University of London.

"I welcome Jamie as our new CEO and I am pleased to concentrate my activities to further demonstrate scientifically the potential of our technology in several viral indications" said Thierry Pelet who is one the co-founders of the company. Thierry will assume the position of Chief Science Officer (CSO).

Viroblock further announced that it has completed its second round of equity funding. The Series B financing round was led by Fongit Seed Invest SA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion) and BlueOcean Ventures acted as co-investors.

"With Jamie and Thierry we have a strong leadership team with proven business skills and accomplished scientific know-how. This team equipped with the additional funding can now start developing our first anti-viral products, which will bring the company to the next level, said Peter Pfister, Chairman of the Board.

About Viroblock

Viroblock is dedicated to developing and commercializing a new generation of anti-viral products with a novel mechanism of action against enveloped viruses. Enveloped viruses represent more than 60% of all existing viruses and include major human pathogens such as human and avian influenzas, the hepatitis B and C viruses and the AIDS virus.

Viroblock's unique proprietary products and technologies open very promising opportunities in a number of prophylactic and therapeutic applications.

Viroblock was founded in October 2005 by the late Donald Wallach, a scientist and academic with past tenure at the Harvard Medical School and Tufts University, and a pioneer in the research of liposome systems.

    For more information:

    Thierry Pelet
    +41-22-884-8344
    info@viroblock.com


SOURCE Viroblock SA


'/>"/>
SOURCE Viroblock SA
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray
2. CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner
3. Professional Reprographics Hires Recent Cal Poly Grad to Join their Team
4. Zeus Expands International Support With New Hires
5. Derma Sciences, Inc. Hires the Investor Relations Group
6. Mirixa Corporation Announces Key New Hires
7. Oppenheimer Announces the Addition of Several Recent Senior Hires in Investment Banking
8. Campbell Alliance Hires Joe Dillon, Expands Business Development Practice
9. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
10. Bio-Matrix Scientific Group Announces New Hires to Management Team
11. Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... Winston-Salem, NC (PRWEB) , ... March 27, 2017 , ... ... Clinical Trial Collaborations (CTC) conference presented by The Conference Forum in Boston ... the way they collaborate to drive improved clinical trial outcomes and bring them closer ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
(Date:3/24/2017)... , March 24, 2017   Sienna Biopharmaceuticals, Inc. ... company, today announced that Richard Peterson will ... 24.   Peterson, who brings more than two ... Smither , who is retiring at the end of ... advisory capacity. Peterson joins Sienna from Novan, Inc., where ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
Breaking Biology Technology:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the leading ... The Prince,s Trust to uncover insights to support its ... Trust. The UK,s leading youth charity will be using ... results and get a better understanding of the topics and issues ... ...
(Date:3/2/2017)... YORK , March 2, 2017 Summary ... better understand Perrigo and its partnering interests and activities since ... ... Partnering Deals and Alliance since 2010 report provides an in-depth ... leading life sciences companies. On demand company reports ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):